Wegovy sales double to boost Novo Nordisk's fourth quarter but slower growth predicted
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of 2024, with analysts and investors describing the results as "good enough" to ease nerves about stiff competition from rival Eli Lilly.
Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug ...
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Novo Nordisk's CEO reassures that side-effects are not an issue in the trial of CagriSema, their next-generation obesity drug. Despite weaker-than-expected trial results, the company is optimistic ...
Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, ...
Novo’s record profit from obesity drugs has given the Foundation a war chest to fund its philanthropic grants, although ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback